TY - JOUR
T1 - Efficacy and tolerability of a fixed dose combination of cortex phospholipid liposomes and cyanocobalermin for intramuscular use in peripheral neuropathies
AU - Scaturro, Dalila
AU - Letizia Mauro, Giulia
AU - Vecchio, Michele
AU - Lauricella, Lorenza
AU - Vecchio, Michele Maria
AU - Tomasello, Sofia
PY - 2019
Y1 - 2019
N2 - Peripheral neuropathies are frequently encourtered in clinical practice and are assiociated with a major impairment in quality of life . Howewvwr, their management reamans poor, and current therapies are often burdened with major side effects and can present poor efficacy on pain and functionality. Therefore, it has been suggested that the combination of two or more different drugs may improve analgesis efficacy and reduce side effects. Tricortin 1000 is formulated with 12 mg of Brain cortex phospholipid liposomes + 1000 microgrammi of Cyanocobalamin injectable (PL+ CNCb1) for intramuscolar use and is indicated in the tratment of poly-algo-neuropathic syndromes. This combination exerts a marked neurotrophic action by promoting the syntesis of endogenous phospholipids; moreover the peculiar formulation optimized the delivery of CNCb1 wich has analgesis and neurotrophic action. This paper discusses the pharmacotherapy of peripheral neuropathies, including low back pain, neck pain, post herpetic neuropathy (PHN) and focuses on the fixed dose combination PL+CNCb1 ckinical efficacy in association with other treatment or in monotherapy.
AB - Peripheral neuropathies are frequently encourtered in clinical practice and are assiociated with a major impairment in quality of life . Howewvwr, their management reamans poor, and current therapies are often burdened with major side effects and can present poor efficacy on pain and functionality. Therefore, it has been suggested that the combination of two or more different drugs may improve analgesis efficacy and reduce side effects. Tricortin 1000 is formulated with 12 mg of Brain cortex phospholipid liposomes + 1000 microgrammi of Cyanocobalamin injectable (PL+ CNCb1) for intramuscolar use and is indicated in the tratment of poly-algo-neuropathic syndromes. This combination exerts a marked neurotrophic action by promoting the syntesis of endogenous phospholipids; moreover the peculiar formulation optimized the delivery of CNCb1 wich has analgesis and neurotrophic action. This paper discusses the pharmacotherapy of peripheral neuropathies, including low back pain, neck pain, post herpetic neuropathy (PHN) and focuses on the fixed dose combination PL+CNCb1 ckinical efficacy in association with other treatment or in monotherapy.
UR - http://hdl.handle.net/10447/361215
M3 - Article
SN - 0026-4806
VL - 110
SP - 455
EP - 463
JO - Minerva Medica
JF - Minerva Medica
ER -